COMPOUNDS COMPRISING STAPLED OR STITCHED PEPTIDES FOR IMPROVED DRUG DELIVERY
The invention relates to improvements in drug delivery and to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (StaP's) or ii) stitching three or more amino acids to form stitched CPP's (StiP's). More particularly there is provided a drug carrying cell penetrating molecule (DCCPM) comprising: a biologically active compound (BAC), and a cell penetrating agent (CPA), which BAC and CPA are linked directly or via a bi-functional linker (BFL). The CPA is a stabilized peptide (CPP) which has a conformation imposed upon it by stapling to form a stapled peptide (StaP) or stitching to form a stitched peptide (StiP). The StiP or StaP comprise a cross link or bridge between at least two amino acids of the peptide and the cross link or bridge provides a cyclisation between at least two amino acids which are not formed by an olefin metathesis. Cyclisation may be achieved by one or more of: condensation of an aldehyde or ketone with a hydrazine or protected hydrazine; a thiol-ene Michael addition; a di-sulfide formation; a Huisgen 1,3 di-polar cycloaddition; a reaction between an amine and carboxylic acid; a singlet or triplet based carbine reaction; or a Suzuki or Sonogashira coupling.
1 . A drug carrying cell penetrating molecule (DCCPM) comprising:
i. a biologically active compound (BAC), and
ii. a cell penetrating agent (CPA),
wherein the BAC and CPA are linked directly or via a bi-functional linker (BFL), the CPA is a stabilized peptide (CPP) which has a conformation imposed upon it by stapling to form a stapled peptide (StaP) or stitching to form a stitched peptide (StiP), the StiP or StaP comprises a cross link or bridge between at least two amino acids of the peptide and the cross link or bridge provides a cyclisation between the at least two amino acids which are not formed by an olefin metathesis.
2 . The DCCPM as claimed in claim 1 , wherein the cyclisation is achieved by one or more of:
i. condensation of an aldehyde or ketone with a hydrazine or protected hydrazine;
ii. a thiol-ene Michael addition;
iii. a di-sulfide formation;
iv. a Huisgen 1,3 di-polar cycloaddition;
v. a reaction between an amine and carboxylic acid;
vi. a singlet or triplet based carbine reaction; or
vii. a Suzuki or Sonogashira coupling.
3 . The DCCPM as claimed in claim 2 , wherein in iv) a triazole is formed between an azide or electron deficient nitrile containing amino acid and a propygyl containing amino acid.
4 . The DCCPM as claimed in claim 3 , wherein the azide is azidolysine.
5 . The DCCPM as claimed in claim 3 , wherein the propygyl containing amino acid is lysine, glutamic acid or aspartic acid.
6 . The DCCPM as claimed in claim 2 , wherein in v) a lactam is formed between a free amine containing amino acid and a carboxylic acid containing amino acid, optionally wherein the lactam is formed by cross linking a lysine and glutamic or aspartic acid.
7 . (canceled)
8 . The DCCPM as claimed in claim 1 , wherein each crosslink has a nominal sequential length of from 2-20 atoms.
9 . The DCCPM as claimed in claim 1 , wherein the stabilized peptide comprises at least one alpha helix, extended 3 10 -helix or poly (Pro) II helix, or at least one beta sheet or hairpin or turn.
10 . (canceled)
11 . The DCCPM as claimed in claim 9 , wherein the stabilized peptide comprises at least one alpha helix, extended 3 10 -helix or poly (Pro) II helix and one beta sheet, turn or hairpin.
12 . The DCCPM as claimed in claim 1 , wherein the BAC is an oligonucleotide (ON).
13 .- 18 . (canceled)
19 . The DCCPM as claimed in claim 1 , wherein the BAC alters the expression of an endogenous or exogenous gene.
20 . (canceled)
21 . The DCCPM as claimed in claim 1 , wherein the BFL comprises a chemistry selected from the chemistries of Table 6.
22 .- 29 . (canceled)
30 . The DCCPM as claimed in claim 1 which is of a size greater than 1.5 KDa.
31 . A method for facilitating the uptake of a biologically active compound (BAC) into a cell comprising
conjugating the biologically active compound to a cell penetrating agent (CPA) which is a stabilized peptide having a conformation imposed upon it by stapling to form a stapled peptide (StaP) or stitching to form a stitched peptide (StiP), wherein the StiP or StaP comprises a cross link or bridge between at least two amino acids of the peptide and the cross link or bridge provides a cyclisation between the at least two amino acids which are not formed by an olefin metathesis, directly or via a bi-functional linker (BFL) to form a drug carrying cell penetrating molecule (DCCPM); and
presenting said DCCPM to said cell in a suitable vehicle.
32 . A method of treating a disease in a subject comprising administering to the subject a DCCPM as claimed in claim 1 , wherein the disease requires alteration of the expression of an endogenous or exogenous gene.
33 . The method of claim 32 , wherein the disease is neuromuscular disease, a metabolic disease, cancer, an age-related degenerative disease or an acquired viral infection.
34 . The method of claim 32 , wherein the disease is Duchenne's muscular dystrophy.
35 . The method of claim 34 , wherein the DCCPM comprises an AO targeting the dystrophin gene.
36 . A method comprising:
linking a drug or BAC to a CPP which is a stabilized peptide which has a conformation imposed upon it by stapling to form a stapled peptide (StaP) or stitching to form a stitched peptide (StiP), wherein the StiP or StaP comprises a cross link or bridge between at least two amino acids of the peptide and the cross link or bridge provides a cyclisation between the at least two amino acids which are not formed by an olefin metathesis, and
administering the linked drug or BAC to a subject,
wherein the method improves the bioavailability of the drug or BAC, or introduces the drug or BAC to a site which is refractory to the drug or BAC in its native state.
37 . (canceled)
38 . The method as claimed in claim 36 wherein the tissue is one of heart, brain, muscle or liver.
39 . (canceled)
40 . A composition comprising the DCCPM as claimed in claim 1 , wherein the composition comprises one or more pharmaceutically acceptable excipients.
41 . (canceled)